Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Daniel H., Ramanathan, Ramesh K., Bekaii-Saab, Tanios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025083/
https://www.ncbi.nlm.nih.gov/pubmed/29891787
http://dx.doi.org/10.3390/cancers10060193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025083/
https://www.ncbi.nlm.nih.gov/pubmed/29891787
http://dx.doi.org/10.3390/cancers10060193

Ejemplares similares